Metformin and breast cancer risk: a meta-analysis and critical literature review

被引:158
|
作者
Col, Nananda F. [1 ,2 ]
Ochs, Leslie [2 ]
Springmann, Vicky [3 ]
Aragaki, Aaron K. [4 ]
Chlebowski, Rowan T. [5 ]
机构
[1] Shared Decis Making Resources, Georgetown, ME 04548 USA
[2] Univ New England, Coll Osteopath Med, Biddeford, ME USA
[3] Univ Montreal, Montreal, PQ, Canada
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
关键词
Metformin; Breast cancer; Meta-analyses; Literature review; DIABETES-MELLITUS; INCIDENT CANCER; MANAGEMENT; OUTCOMES; COHORT; DRUGS; WOMEN;
D O I
10.1007/s10549-012-2170-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Observational studies have suggested that metformin decreases the incidence of several common cancers. However, findings regarding breast cancer have been mixed. In order to explore this issue, a systematic literature review and meta-analysis were performed with a focus on potential biases. We conducted a comprehensive literature search for all pertinent studies addressing metformin use and breast cancer risk by searching PubMed, Cochrane Library, and Scopus (which includes Embase, ISI Web of Science) using the Mesh terms: "metformin" or "biguanides" or "diabetes mellitus, type 2/therapy" and "cancer" or "neoplasms." When multiple hazard ratios (HR) or odds ratio (OR) were reported, the most adjusted estimate was used in the base-case analysis. We pooled the adjusted HR and performed sensitivity analyses on duration of metformin use (> or a parts per thousand currency sign3 years use), study quality (assessed using the GRADE system), and initial observation year of the cohort (before vs after 1997). From a total of 443 citations, 18 full-text articles were considered, and seven independent studies were included. All were observational (four cohort and three case control). Our combined OR of all seven studies was 0.83 (0.71-0.97). Stronger associations were found when analyses were limited to studies estimating the impact of longer metformin use (OR = 0.75. 95 % CI 0.62, 0.91) or among studies that began observing their cohort before 1997 (OR = 0.68. 95 % CI 0.55-0.084). Stratification according to study quality did not affect the combined OR but higher quality studies had smaller CI and achieved statistical significance. Interpretation is limited by the observational nature of reports and different comparison groups. Our analyses support a protective effect of metformin on breast cancer risk among postmenopausal women with diabetes. Clinical trials are needed for definitive determination of the role of metformin in breast cancer risk reduction.
引用
收藏
页码:639 / 646
页数:8
相关论文
共 50 条
  • [1] Metformin and breast cancer risk: a meta-analysis and critical literature review
    Nananda F. Col
    Leslie Ochs
    Vicky Springmann
    Aaron K. Aragaki
    Rowan T. Chlebowski
    Breast Cancer Research and Treatment, 2012, 135 : 639 - 646
  • [2] Metformin and breast cancer risk: A meta-analysis and critical literature review.
    Col, Nananda
    Ochs, Leslie
    Springmann, Vicky
    Aragaki, Aaron K.
    Chlebowski, Rowan T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [3] Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis, with Special Emphasis to Breast Cancer
    DeCensi, A.
    Puntoni, M.
    Goodwin, P.
    Cazzaniga, M.
    Gennari, A.
    Bonanni, B.
    Gandini, E. O. S.
    CANCER RESEARCH, 2010, 70
  • [4] Metformin Versus Sulfonylurea in Breast Cancer Risk of Diabetic Patients: A Systematic Review and Meta-Analysis
    Moradi-Joo, Mohammad
    Mohabbat-Bahar, Sahar
    Heidari, Saeed
    Davoodi, Sayed Hossein
    Sheyklo, Sepideh Gareh
    Akbari, Mohammad-Esmaeil
    IRANIAN JOURNAL OF CANCER PREVENTION, 2016, 9 (05)
  • [5] Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis
    Lu, Yifan
    Hajjar, Ali
    Cryns, Vincent L.
    Trentham-Dietz, Amy
    Gangnon, Ronald E.
    Heckman-Stoddard, Brandy M.
    Alagoz, Oguzhan
    CANCER MEDICINE, 2023, 12 (10): : 11703 - 11718
  • [6] Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
    DeCensi, Andrea
    Puntoni, Matteo
    Goodwin, Pamela
    Cazzaniga, Massimiliano
    Gennari, Alessandra
    Bonanni, Bernardo
    Gandini, Sara
    CANCER PREVENTION RESEARCH, 2010, 3 (11) : 1451 - 1461
  • [7] Breast Cancer Diagnosis by Scintimammography: A Meta-analysis and Review of the Literature
    Moishe Liberman
    Fotini Sampalis
    David S. Mulder
    John S. Sampalis
    Breast Cancer Research and Treatment, 2003, 80 : 115 - 126
  • [8] Breast cancer diagnosis by scintimammography: a meta-analysis and review of the literature
    Liberman, M
    Sampalis, F
    Mulder, DS
    Sampalis, JS
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 (01) : 115 - 126
  • [9] Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
    Noto, Hiroshi
    Goto, Atsushi
    Tsujimoto, Tetsuro
    Noda, Mitsuhiko
    PLOS ONE, 2012, 7 (03):
  • [10] IS METFORMIN ASSOCIATED WITH LOWER RISK OF COLORECTAL CANCER? SYSTEMATIC REVIEW AND META-ANALYSIS
    Kamal, Faisal
    Khan, Muhammad Ali
    Sharma, Sachit
    Imam, Zaid
    Jowhar, Dawit
    Zafar, Muhammad Usman
    Petryna, Ellen
    Saleem, Nasir
    Sami, Khadija N.
    Henry, Collin
    Iqbal, Umair
    Howden, Colin W.
    GASTROENTEROLOGY, 2021, 160 (06) : S323 - S323